Artificial intelligence is being asked to do more than write messages, generate images or answer questions. A London-based company spun out of Google DeepMind is using it to help design medicines, and investors have put $5 billion behind its next stage of work.
Isomorphic Labs announced a $5 billion Series C funding round on November 17, co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz and other new investors also participated, alongside continued investment from Alphabet and the company’s existing backers. The company says the funding will help scale its AI drug-design engine and move its pipeline of potential medicines towards clinical development.
The scale of the investment raises a question with consequences beyond the technology industry: could AI help scientists find new treatments for diseases faster, and perhaps make medicines possible that are difficult to develop using conventional methods?
What does Isomorphic Labs do?
Founded in 2021 as a spin-off from Google DeepMind, Isomorphic Labs applies artificial intelligence to the design and development of new medicines. It was founded by Demis Hassabis, the Google DeepMind co-founder and Nobel Prize-winning scientist whose work includes the AlphaFold system for predicting protein structures.
Proteins play essential roles in the human body, and many medicines work by interacting with particular proteins or other biological targets. Understanding their structures and behaviour can help researchers identify where a drug might bind and how it could affect a disease process. AI models can help scientists explore these complex interactions and narrow down which molecules are worth testing.
Isomorphic’s proprietary platform, called the Isomorphic Labs Drug Design Engine (IsoDDE), brings together simulation-based AI models designed to work across different therapeutic areas and types of medicines. The company says the system helps its researchers explore chemical possibilities and design molecules with properties that could make them suitable drug candidates.
Where could the research make a difference?
Isomorphic says its internal programmes include work in oncology and immunology, and that it has seen positive preclinical results. It is also working with pharmaceutical companies including Eli Lilly, Novartis and Johnson & Johnson on drug-discovery programmes.
These areas matter because many diseases involve complicated biological systems. Cancer, for example, can involve multiple pathways and changes in how cells grow and respond to treatment. Immunological conditions can also be difficult to address because the immune system involves many interacting cells and signals. Better tools for modelling those systems could help researchers identify and test promising drug candidates.
That is the promise, rather than a proven patient benefit. Isomorphic has not announced an approved medicine emerging from its platform. Its reported results are preclinical, meaning they come before testing in people.
Why is the funding significant?
The new investment follows a $2.1 billion Series B round announced in May 2026. The latest funding is intended to expand the company’s drug-design technology, advance its candidate pipeline and build the infrastructure needed for clinical development.
Drug discovery is a lengthy and uncertain process. A molecule that appears promising in computer models or laboratory experiments must still be studied for safety and effectiveness. It must pass through several stages of testing, including clinical trials involving people, and meet regulatory requirements before it can be made available as a medicine. Many candidates do not make it through that process.
AI could help researchers assess more possibilities, prioritise experiments and reduce some of the trial-and-error involved in early discovery. But it cannot, by itself, establish that a treatment is safe or that it works in patients. Those questions can only be answered through rigorous testing.
Can AI really find a life-saving drug?
It is too early to know whether Isomorphic’s approach will produce a breakthrough medicine. The $5 billion round is a major vote of confidence from investors, but it is not evidence that a drug has been discovered or that development timelines will necessarily become shorter.
The real test will be whether AI-designed candidates can move from promising models and preclinical research into successful human trials, and eventually become treatments that doctors can prescribe. If that happens, the impact could extend well beyond the technology sector, potentially giving researchers new ways to tackle diseases for which treatment options remain limited.
For now, Isomorphic Labs represents one of the most ambitious efforts to bring AI into biomedical research. The investment gives it substantial resources to pursue that goal. Whether those resources translate into safer, more effective medicines is a question that only the science and the clinical evidence can answer.
Sources: Isomorphic Labs funding announcement; Reuters; Chemical & Engineering News.



